A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
Latest Information Update: 19 Apr 2025
At a glance
- Drugs AH 001 (Primary)
- Indications Alopecia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AnHorn Medicines
Most Recent Events
- 02 Apr 2025 New trial record
- 26 Mar 2025 According to AnHorn Medicines, first subject was dosed in this study in the last week of March 2025.